Tegoprubart and the CD40L Pathway: Promise and Remaining Questions in CNI-Free Kidney Transplantation
BioNatura Journal: Ibero-American Journal of Biotechnology and Life Sciences · 13.05.2026
DOI: 10.70099/bj/2026.03.02.10 ↗Kurz gefasst
Fachartikel in der Zeitschrift BioNatura Journal: Ibero-American Journal of Biotechnology and Life Sciences, online erschienen am 13.05.2026. Verfasst von Maria Cassola und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Calcineurin inhibitors (CNIs), particularly tacrolimus, remain the cornerstone of maintenance immunosuppression in kidney transplantation. However, their long-term use is limited by dose-dependent nephrotoxicity, metabolic complications including new-onset diabetes after transplantation (NODAT), neurotoxicity, and progressive allograft dysfunction. These limitations have driven the search for alternative strategies capable of preserving graft function while minimizing toxicity. Tegoprubart (AT-1501) is a next-generation, humanized, Fc-silent monoclonal antibody targeting CD40 ligand (CD40L), a critical mediator of T cell–B cell costimulatory signaling. By selectively blocking the CD40/CD40L pathway, tegoprubart inhibits germinal center formation, suppresses B cell activation, and prevents donor-specific antibody (DSA) development, thereby addressing both cellular and humoral alloimmune responses. Importantly, Fc engineering eliminates Fcγ receptor binding, mitigating the platelet activation and thromboembolic complications observed with earlier anti-CD40L therapies. Preclinical studies in non-human primate models and emerging clinical data, including results from the BESTOW Phase 1b/2 program, demonstrate that tegoprubart-based regimens are associated with preserved or improved renal function, low rates of acute rejection, absence of NODAT, and a favorable safety profile. Comparative analyses suggest potential advantages over tacrolimus-based regimens and CD40-targeting approaches, particularly in maintaining long-term graft integrity. Despite these promising findings, current evidence remains limited by small sample sizes, short follow-up, and early-phase trial designs. Ongoing Phase 3 studies are required to confirm long-term efficacy, safety, and applicability across broader transplant populations. Tegoprubart represents a promising CNI-free immunosuppressive strategy with the potential to redefine maintenance therapy in kidney transplantation by improving long-term outcomes while reducing treatment-related toxicity.
Zitieren
APA
Cassola, M., & Niebla, O. J. L. (2026). Tegoprubart and the CD40L Pathway: Promise and Remaining Questions in CNI-Free Kidney Transplantation. BioNatura Journal: Ibero-American Journal of Biotechnology and Life Sciences. https://doi.org/10.70099/bj/2026.03.02.10
Vancouver
Cassola M, Niebla OJL. Tegoprubart and the CD40L Pathway: Promise and Remaining Questions in CNI-Free Kidney Transplantation. BioNatura Journal: Ibero-American Journal of Biotechnology and Life Sciences. 2026. doi:10.70099/bj/2026.03.02.10
BibTeX
@article{Cassola2026,
author = {Cassola, Maria and Niebla, Omar Junior Leal},
title = {Tegoprubart and the CD40L Pathway: Promise and Remaining Questions in CNI-Free Kidney Transplantation},
journal = {BioNatura Journal: Ibero-American Journal of Biotechnology and Life Sciences},
year = {2026},
doi = {10.70099/bj/2026.03.02.10}
}
EUVIMED